The partnership with Vinmec Healthcare System demonstrates the confidence in our technology and supports our long-term ...
Artiva advances NK cell therapy to phase 3, secures 400 billion won funding Single phase 3 cleared by FDA after strong phase 2 ACR50 results; $300 million raised from global investors ...
Morning Overview on MSN
McGill scientists just supercharged the body’s natural killer cells to punch through the walls tumors build to survive — restoring an immune defense cancer had switched off
Natural killer cells are supposed to be the immune system’s first responders against cancer. They don’t need to be trained on ...
Fortis Life Sciences today announces the introduction of the AbNano ® VHH Anti-NK Cell Library, a first-in-class peripheral natural killer (NK) cell-derived single-domain antibody (VHH) repertoire for ...
Chinese researchers have developed a novel method to efficiently engineer natural killer (NK) cells for cancer immunotherapy. NK cells are central to early antiviral and anticancer defense—among other ...
A new review article highlights the powerful influence of long non-coding RNAs (lncRNAs) in regulating natural killer (NK) cells, revealing promising opportunities to enhance immune responses and ...
Next-generation multispecific antibody, ISB 2301, targets 3 tumor-associated antigens (TAAs) and activates both T cells and natural killer (NK) ...
One of the newest weapons that scientists have developed against cancer is a type of engineered immune cell known as CAR-NK (natural killer) cells. Similar to CAR-T cells, these cells can be ...
ImmunityBio Inc. (NASDAQ:IBRX) is one of the 10 Must-Watch Stocks Right Now. ImmunityBio surged by 7.29 percent on Friday to finish at $8.39 apiece, as investors took heart from the company’s optimism ...
The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results